721 related articles for article (PubMed ID: 28323111)
1. Nanoparticles for tumor immunotherapy.
Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticulate immunotherapy for cancer.
Kapadia CH; Perry JL; Tian S; Luft JC; DeSimone JM
J Control Release; 2015 Dec; 219():167-180. PubMed ID: 26432555
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
[TBL] [Abstract][Full Text] [Related]
4. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based immunotherapy for cancer.
Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
[TBL] [Abstract][Full Text] [Related]
6. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
[TBL] [Abstract][Full Text] [Related]
7. Drug Delivery for Cancer Immunotherapy and Vaccines.
Batty CJ; Tiet P; Bachelder EM; Ainslie KM
Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
[TBL] [Abstract][Full Text] [Related]
8. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective.
Lan H; Zhang W; Jin K; Liu Y; Wang Z
Drug Deliv; 2020 Dec; 27(1):1248-1262. PubMed ID: 32865029
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
10. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
11. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
12. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
Zhang M; Kim JA; Huang AY
Front Immunol; 2018; 9():341. PubMed ID: 29535722
[TBL] [Abstract][Full Text] [Related]
14. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.
Lim S; Park J; Shim MK; Um W; Yoon HY; Ryu JH; Lim DK; Kim K
Theranostics; 2019; 9(25):7906-7923. PubMed ID: 31695807
[TBL] [Abstract][Full Text] [Related]
15. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
Hameed S; Bhattarai P; Dai Z
Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based immunity-inducing systems for cancer immunotherapy.
Yuba E
Mol Immunol; 2018 Jun; 98():8-12. PubMed ID: 29128232
[TBL] [Abstract][Full Text] [Related]
17. Targeting Immunotherapy to the Tumor Microenvironment.
Dougan M; Dougan SK
J Cell Biochem; 2017 Oct; 118(10):3049-3054. PubMed ID: 28332219
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional nanoparticles for cancer immunotherapy.
Saleh T; Shojaosadati SA
Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
[TBL] [Abstract][Full Text] [Related]
19. Multi-Immune Agonist Nanoparticle Therapy Stimulates Type I Interferons to Activate Antigen-Presenting Cells and Induce Antigen-Specific Antitumor Immunity.
Levy ES; Chang R; Zamecnik CR; Dhariwala MO; Fong L; Desai TA
Mol Pharm; 2021 Mar; 18(3):1014-1025. PubMed ID: 33541072
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
